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Abstract 
Rationale–Diverse B cell responses and functions may be involved in atherosclerosis. 
Protective antibody responses, such as those against oxidized lipid epitopes, are thought to 
mainly derive from T cell-independent innate B cell subsets. In contrast, both pathogenic and 
protective roles have been associated with T cell-dependent antibodies and their importance 
in both humans and mouse models is still unclear. 
Objective– To specifically target antibody production by plasma cells and determine the 
impact on atherosclerotic plaque development in mice with and without CD4+ T cells. 
Methods and Results– We combined a model of specific antibody deficiency, B cell-specific 
CD79a-Cre x X-box binding protein-1 (XBP1) floxed mice (XBP1-cKO), with antibody 
mediated depletion of CD4+ T cells. Ldlr knockout mice transplanted with XBP1-cKO (or WT 
control littermate) bone marrow were fed western diet for 8 weeks with or without anti-CD4 
depletion. All groups had similar levels of serum cholesterol. In Ldlr/ XBP1-cKO mice, serum 
levels of IgG, IgE and IgM were significantly attenuated, and local antibody deposition in 
atherosclerotic plaque was absent. Antibody deficiency significantly accelerated 
atherosclerosis at both the aortic root and aortic arch. T cell and monocyte responses were 
not modulated, but necrotic core size was greater, even when adjusting for plaque size, and 
collagen deposition significantly lower. Anti-CD4 depletion in Ldlr/WT mice led to a decrease 
of serum IgG1 and IgG2c but not IgG3, as well as decreased IgM, associated with increased 
atherosclerosis and necrotic cores, and a decrease in plaque collagen. The combination of 
antibody deficiency and anti-CD4 depletion has no additive effects on aortic root 
atherosclerosis. 
Conclusions– The endogenous T cell-dependent humoral response can be protective. This 
has important implications for novel vaccine strategies for atherosclerosis and in 
understanding the impacts of immunotherapies used in patients at high risk for 
cardiovascular disease. 
Keywords: Antibodies, B cells, Atherosclerosis 
Non-standard Abbreviations and Acronyms: BSA – bovine serum albumin; CGG – 
chicken gamma globulin; cKO – conditional knockout; DC – dendritic cell; GC – Germinal 
centre; LDL – low density lipoprotein; MDA – malondialdehyde; MAA – malondialdehyde 
acetaldehyde; NP – nitrophenyl; OSE - oxidation-specific epitope; PC – phoshorylcholine; 
sIgM – soluble IgM; sma – smooth muscle actin; Teff – effector T cells; Tfh – follicular helper 
T cells; Treg – regulatory T cells, TUNEL - Terminal deoxynucleotidyl transferase dUTP nick 
end labeling; XBP1 – Xbox-binding protein-1. 
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Introduction 
The subendothelial accumulation of low density lipoprotein (LDL) is central to the initiation 
and progression of atherosclerotic plaques. Modification of LDL, and a consequent shift in 
recognition, uptake and intracellular processing (or lack of) by phagocytes play a key role in 
foam cell formation, sustaining inflammation and necrotic/lipid core formation. In contrast to 
early phagocytosis of apoptotic cells, which is anti-inflammatory, secondary necrosis can be 
highly pro-inflammatory1, recruiting and activating immune cells. A current paradigm for 
atherosclerosis proposes that the combination of extracellular lipid accumulation, foam cell 
formation and defective efferocytosis leads to a non-resolving loop of inflammation, debris 
accumulation and response to injury. 
Oxidative modifications of LDL and cellular membranes create immunogenic epitopes 
recognized by antibodies2. B cell antibody responses can be divided broadly into 3 
categories. Innate-like IgM production, primarily from B1 cells but also marginal zone B cells, 
occurs against common molecular pattern antigens such as malondialdehyde (MDA) and 
phosphorylcholine (PC) and is present perinatally and even in germ-free mice3. Responses 
to other antigens also initially result in IgM production from short-lived plasmablasts and 
plasma cells but then undergo various forms of adaptation. T cell-independent responses 
can adapt via class-switching of IgM to other isotypes such as IgA). T cell help from antigen-
specific CD4+ T cells leads to both class-switching and multiple rounds of affinity maturation 
within germinal centers of lymphoid organs, resulting in high affinity antibodies and memory 
B cells4. Antibodies to modified LDL in atherosclerosis are produced through each different 
mode. The origins of responses to other antigens in atherosclerosis is not well understood. 
Many studies have assessed levels of antibodies against oxidized forms of LDL and more 
recently to the specific epitopes MDA and PC. High levels of IgM type antibodies to MDA 
and PC reduce the risk for cardiovascular disease5–7, although not in all studies8,9. In 
contrast, IgG antibodies of similar specificity can in some cases be positively associated with 
disease10 but more commonly show no association5,8,9. Recently, total serum IgG and IgM, in 
addition to oxLDL-specific, was associated with reduced risk of cardiovascular events9. 
In mice, many studies suggest IgM antibodies provide an important atheroprotective layer 11–
15. The specific effect of deleting IgM antibodies (rather than B cells in general) was first 
addressed by Lewis et al16. Mice lacking soluble IgM (but not B cell surface IgM or other 
isotypes of antibodies) have increased atherosclerosis16. However, in a more recent study 
using sIgM-/-/Ldlr-/- mice, we demonstrated that the enhanced atherosclerosis was a result of 
IgE accumulation in the circulation since anti-IgE injections completely reversed the 
phenotype17. IgE accumulates because sIgM-/- mice have a significant reduction in IgE 
receptor (CD23)-expressing B cells, leading to mast cell activation and pro-atherogenic 
inflammation. This raises important questions about the direct role of IgM or related 
downstream biological events in mediating atheroprotection. IgG antibodies against modified 
LDL may also be protective, for example passive transfer of a human IgG1 against an MDA-
modified apoB100 peptide reduces mouse atherosclerosis18. Recombinant Fab’ and single 
chain forms of anti-MDA-LDL antibodies, that lack the normal Fc-mediated effects of 
antibodies, also reduce foam cell formation and atherosclerosis19. However, several studies 
also implicate a pathogenic role for IgG in atherosclerosis, albeit indirectly20–22, and vascular 
pathologies such as chronic cardiac rejection and large vessel vasculitis are thought to be 
driven by pathogenic autoantibodies23,24.  
Emerging paradigms reveal many non-antibody dependent functions of B cells that could 
play important roles in atherosclerosis25–27. We and others have shown follicular B2 cell 
interactions with CD4+ T cells, antagonized by marginal zone B2 cells, promote pathogenic T 
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cell responses in the atherosclerotic setting28–33. Few models have therefore addressed the 
specific role of antibodies in isolation without impacting on other B cell functions. Altogether, 
it is hard to predict the effects of total antibody deficiency on atherosclerosis. We designed 
experiments to target plasma cell antibody production specifically. Plasma cells undergo a 
profound transcriptional reprogramming during differentiation from activated B cells; a 
prominent set of genes induced in plasma cells are regulators of the endoplasmic reticulum 
stress pathway, which expands antibody secretion capacity34. A key transcription factor is 
Xbox-binding protein-1 (Xbp1), and previous studies have characterized in detail that mice 
with B cell-specific Xbp1 genetic deletion display a specific defect in antibody production35–37. 
Using this model under the atherosclerotic Ldlr-/- background, we demonstrate that Xbp1-
dependent plasma cell responses have a prominent anti-atherosclerotic influence. 
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Methods 
Mice 
CD79aCre mice were original created in the Reth lab38 and were obtained from Jackson labs 
(020505). Xbp1fl/fl mice were originally created in the Glimcher lab39 and were a gift of Prof. 
A. Kaser, University of Cambridge. Ldlr-/- mice were originally obtained from Jackson labs 
(002207). A total of 53 male Ldlr-/- mice were used in the study. Antigen-specific antibody 
responses were induced by immunization with nitrophenyl-chicken gamma globulin (NP-
CGG; 100µg; Biosearch) in alum. Creation of bone marrow chimeric mice, atherosclerosis 
experiments and anti-CD4 depletion have been previously described40. Mice from different 
experimental groups were co-housed for atherosclerosis experiments.  This research has 
been regulated under the Animals (Scientific Procedures) Act 1986 Amendment Regulations 
2012 following ethical review by the University of Cambridge Animal Welfare and Ethical 
Review Body (AWERB). 
Plaque and serum analysis 
To assess plaque size and composition, aortic root cryosections were stained with Oil red O 
(Sigma), CD3 (Dako), MOMA2 (Biorad), α-smooth muscle actin (Sigma), IgM (Biolegend), 
IgG1 (Bethyl Labs), picrosirius red (Sigma), and by terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL; Roche). Oil red O stained aortic arches were dissected and 
imaged en face. Images were analyzed using ImageJ (NIH). Serum antibodies were 
analyzed using kits from Bethyl labs and total cholesterol using a cholesterol RTU kit 
(Biomerieux). Triglyceride levels were measured using LabAssay kit (Wako). Antibodies 
against oxidation-specific epitopes (OSE) were measured as previously described15. 
Immune cell phenotyping 
Flow cytometry of single cell suspensions was performed as previously described40. Flow 
cytometry antibodies are detailed in supplementary table 1 and gating strategies are outlined 
in supplemental table 2. For ELISpot assays, multiscreen 96-well filter plates (Millipore) were 
coated with anti-mouse total IgM or IgG (Bethyl labs) overnight, blocked with PBS/1% bovine 
serum albumin (BSA), then incubated with 104-106 bone marrow or spleen cells overnight. 
For NP-specific antibody detection, plates were coated with NP-BSA (Biosearch). Staining 
was revealed with anti-mouse IgG-horseradish peroxidase (Southern Biotech) or anti-mouse 
IgM- horseradish peroxidase (Bethyl labs) and 3,3',5,5'-tetramethylbenzidine substrate 
(MABtech). Plates were analyzed using an Immunospot reader (CTL Technologies). 
Regulatory T cell suppression assays were conducted using magnetically purified cells 
(Miltenyi) as previously described29. 
Statistics 
Data was analyzed in GraphPad Prism (La Jolla, CA, USA) using unpaired T test (or Mann 
Whitney U test for data sets not passing normality), one-way ANOVA or two-way ANOVA, as 
appropriate. A p value <0.05 was considered significant.  
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Results 
Xbp1 deficiency in B cells attenuates plasma cell antibody production 
To obtain a mouse model with a specific defect in antibody secretion, we recreated a 
previously reported B cell-specific deletion of the transcription factor XBP1, which is required 
for terminal plasma cell differentiation but not antecedent stages of B cell development, 
maintenance of mature B cells, germinal center (GC) B cell or memory B cell formation 35–37. 
Mice carrying a floxed allele of the Xbp1 gene were crossed to Cd79aCre/+ mice that express 
Cre only in B cells38. To confirm the phenotype of these mice, we performed ELISpot 
analysis of total IgM and IgG-producing bone marrow plasma cells (supplemental figure 1A). 
Plasma cells from Cd79a+/+ x Xbp1fl/fl mice (wildtype; WT) formed large spots of IgM and IgG. 
In contrast, plasma cells from Cd79aCre/+ x Xbp1fl/fl mice (referred to hereafter as Xbp1 B cell-
conditional knockout; Xbp1B-cKO) formed only small IgM producing spots with very few IgG 
producing spots detected (supplemental figure 1A). In addition to this baseline phenotype, 
we also analyzed the antigen-specific response. Xbp1B-cKO mice and WT littermates were 
immunized with NP-CGG and after 7 days bone marrow NP-specific plasma cells and serum 
NP-specific IgG were analyzed. Compared to PBS-immunized controls in which NP-specific 
responses were undetectable, we detected NP-specific IgG1 secreting plasma cells in WT 
mice. In Xbp1B-cKO mice, NP-specific plasma cells were present but reduced around 2-fold 
(supplemental figure 1B). NP-specific IgG1 levels in the serum from the same mice were 
around 16-fold less in Xbp1B-cKO than WT mice, with no detectable antibodies in PBS-
immunized mice (supplemental figure 1C). The difference in antibody titer was therefore 
more severely affected than the difference in antibody producing plasma cells, consistent 
with the idea that plasma cells can form in the absence of XBP1, but their antibody 
production is severely impaired. As previously reported35, total numbers of CD138+ B220- 
plasma cells were normal in bone marrow by flow cytometry (supplemental figure 1D).  
B cell deletion of Xbp1 in atherosclerotic mice specifically attenuates antibody 
production 
To determine the impact of antibody deficiency on atherosclerosis, we then used Xbp1B-cKO 
and WT littermates as bone marrow donors to irradiated Ldlr-/- mice that develop 
atherosclerosis. After 4 weeks recovery, Ldlr-/- recipients were fed a western diet for 8 
weeks. Since atherosclerosis may be affected by both T cell-dependent and independent 
antibody responses, but the role of T cell-dependent responses is much less clear, we 
treated subgroups of Ldlr-/-/WT and Ldlr-/-/Xbp1B-cKO chimeras with depleting anti-CD4 
antibodies for the duration of the western diet feeding40. Littermate (and co-housed) Ldlr-/- 
recipients were split evenly among the 4 groups. In both groups of mice treated with anti-
CD4 antibodies, depletion was maintained to a high level between injections, with only minor 
levels of CD4+ T cell recovery detected immediately before the subsequent injection 
(supplemental figure 1E). 
To confirm that defective antibody production seen in Xbp1B-cKO mice was reproduced in 
atherosclerotic Ldlr-/- chimeras, we analyzed total IgG, IgE, IgA and IgM in serum using 
specific ELISAs. We also measured subtypes of IgG including T cell-dependent total IgG2c 
and T cell-independent IgG3. All isotypes were significantly reduced in Ldlr-/-/Xbp1B-cKO mice 
compared to Ldlr-/-/WT controls, except for IgA (figure 1A-H). Anti-CD4 depletion significantly 
reduced IgG2c but not IgG3 as expected (figure 1G+H). Total IgG, IgE and IgA was not 
affected by anti-CD4 depletion, whereas total IgM was significantly reduced, almost to levels 
in Ldlr-/-/Xbp1B-cKO mice (figure 1C). This suggested that a significant proportion of IgM 
production in atherosclerotic Ldlr-/-/WT mice was CD4+ T cell-dependent.  
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We then analyzed the status of immune cells and tissues in Ldlr-/-/WT and Ldlr-/-/Xbp1B-cKO 
mice by flow cytometry. Total cell numbers in spleen, lymph nodes, bone marrow and 
peritoneum were not different between Ldlr-/-/Xbp1B-cKO and Ldlr-/-/WT controls (supplemental 
figure 2). XBP1 is primarily expressed during plasma cell differentiation and is not reported 
to have major functions in B cells. However, the lack of antibodies may have feedback 
influences on the B cell compartment. We therefore performed detailed flow cytometry 
phenotyping of B cell subsets in bone marrow, spleen and peritoneum, including peritoneal 
B1 cells and splenic marginal zone B cells that are known to regulate atherosclerosis13,33,41. 
There were no differences in bone marrow B cell fractions in Ldlr-/-/Xbp1B-cKO mice or after 
anti-CD4 depletion (supplemental figure 3A). In the spleen, there was an expansion of 
marginal zone B cells (figure 1I), similar to the phenotype of IgM-deficient sIgM-/- Ldlr-/- 
mice17. Splenic B1 cells tended to expand in Ldlr-/-/Xbp1B-cKO mice, but this difference did not 
reach significance (supplemental figure 3B). This expansion of innate-like B cells was 
specific to the spleen as no differences in B1 or B2 cells were detected in the peritoneum 
(supplemental figure 3C). Ldlr-/-/Xbp1B-cKO mice did not display significant differences in 
follicular B2 cells, whereas anti-CD4 depletion led to an expansion of splenic follicular B2 
cells in WT but not cKO chimeras (figure 1I). Ldlr-/-/Xbp1B-cKO mice displayed no changes in 
spleen GC B cells or in plasma cell numbers in bone marrow (figure 1J+K). In contrast, GC 
B cells were absent from both anti-CD4 treated groups (figure 1J), providing functional 
evidence of successful CD4 depletion. This is also consistent with a severe reduction in GC-
dependent IgG1 and IgG2c antibody levels (figure 1G). Anti-CD4 treated mice tended to 
have less plasma cells, which was significant in Ldlr-/-/Xbp1B-cKO (figure 1K). There was also 
a trend towards an increased proportion of IgM+ plasma cells in Ldlr-/-/WT mice treated with 
anti-CD4 compared to Ldlr/WT controls, consistent with less class-switched responses 
(supplemental figure 3D).  
Xbp1 deficiency in B cells does not modulate systemic T cell immune responses 
We and others have previously shown that global B2 cell or specific marginal zone B cell 
depletion can have significant impacts on CD4+ T cell effector responses that promote 
atherosclerosis28–30,33. Total CD4+ and CD8+ T cells numbers were not different between Ldlr-
/-/WT and Ldlr-/-/Xbp1B-cKO mice (supplemental figure 3E). In contrast to B cell depletion 
models, pro-atherogenic effector T cells (Tem; CD62L- CD44hi) (figure 2A and supplemental 
figure 3F), proportions of CD4+ T cells secreting IFN-γ (figure 2B) and follicular helper T cells 
(Tfh; figure 2C) were not different between Ldlr-/-/WT and Ldlr-/-/Xbp1B-cKO mice. Spleen 
dendritic cell (DC) numbers were not different between Ldlr-/-/WT and Ldlr-/-/Xbp1B-cKO groups 
(figure 2D), however we observed a significant reduction in MHCII levels on both CD8α+ and 
CD11b+ cDCs, but not plasmacytoid DCs (figure 2E). This difference was not observed in 
anti-CD4 depleted mice (figure 2E) and MHCII is not expected to have any significant 
function in those mice. The modest reduction of MHCII in Ldlr-/-/Xbp1B-cKO mice does not 
appear to have impacted on effector T cell responses (figure 2A-C), but we hypothesized 
that differences in DC antigen presentation could have compromised regulatory T cell 
function42. However, the levels of spleen Treg were not different in Ldlr-/-/Xbp1B-cKO mice (Treg; 
figure 2F). To assess the function of Treg cells, we magnetically sorted naïve/effector T cells 
(Teff; CD4+ CD25-), Treg (CD4+ CD25+) and cDCs (CD11c+). The proliferation of Teff was 
induced by anti-CD3 in the presence of cDCs. The suppressive capacity of regulatory T cells 
was titrated by adding CD4+ CD25+ cells at different ratios from 1:1 (Treg: Teff) to 1:8 and 
comparing proliferation, measured by 3H-thymidine incorporation, to Teff cells in the absence 
of Treg. The suppressive capacity of Ldlr-/-/Xbp1B-cKO Treg was comparable to Ldlr-/-/WT Treg 
at all ratios, suggesting an intact regulatory T cell system (figure 2G). The levels of 
circulating monocytes or neutrophils did not significantly differ between any groups 
(supplemental figure 4A+B). Overall, we concluded that Ldlr-/-/Xbp1B-cKO mice had a specific 
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deficiency in antibody production without impacting systemically on cellular immune 
responses. 
Xbp1 deficiency in B cells enhances atherosclerosis 
The development of atherosclerosis was quantified in the aortic root and the aortic arch by 
oil red O staining (figure 3A). Analysis of serial aortic root cryosections revealed enhanced 
atherosclerosis in Ldlr-/-/Xbp1B-cKO mice (figure 3B; p<0.001). Similarly, atherosclerosis in the 
aortic arch analyzed en face had advanced more rapidly in Ldlr-/-/Xbp1B-cKO mice than in Ldlr-
/-/WT controls (figure 3C). In the aortic root, anti-CD4 depletion resulted in increased 
atherosclerosis to a similar level as that seen in Ldlr-/-/Xbp1B-cKO mice. There was no further 
increase in atherosclerosis in Ldlr-/-/Xbp1B-cKO mice treated with anti-CD4 (figure 3B). The 
same pattern was seen in the aortic arch, although both CD4-depleted groups had higher 
levels of atherosclerosis (figure 3C). The levels of circulating total cholesterol or triglycerides 
were not different between any groups (supplemental figure 4C+D). The body weight of Ldlr-
/-/Xbp1B-cKO mice was higher than other groups, an effect not observed in anti-CD4 treated 
groups (supplemental figure 4E). 
Xbp1 deficiency in B cells and anti-CD4 depletion reduce oxidized epitope-specific 
antibodies 
Based on increased atherosclerosis in both Ldlr-/-/Xbp1B-cKO and anti-CD4 treated mice, and 
decreased levels of IgM, we determined the levels of OSE-specific antibodies. IgM levels to 
MDA, malondialdehyde-acetaldehyde (MAA) and PC epitopes (conjugated to BSA) are 
presented in Figure 4A-C and showed a similar trend to total antibody levels (Figure 1). A 
prototypic B1 cell natural antibody, T15, is detected using anti-idiotypic AB1-2 antibodies. 
Again, as expected, serum T15 titers were significantly reduced in Ldlr-/-/Xbp1B-cKO mice 
(Figure 4D). Interestingly, anti-CD4 depletion in Ldlr-/-/WT mice also resulted in significantly 
reduced levels (Figure 4D). Serum IgG antibody titers to MDA, MAA and PC were severely 
reduced by B cell XBP1 deficiency and anti-CD4 depletion (figure 4E-G). We also analyzed 
IgG subtype antibodies to MDA-LDL (Figure 4H). All isotypes except IgG3 were significantly 
reduced in Ldlr-/-/Xbp1B-cKO mice. Anti-CD4 depletion had a larger effect on IgG2c than IgG1 
or IgG2b, consistent with effects on total IgG levels (figure 1). Thus, all treatment groups with 
enhanced atherosclerosis displayed an attenuation of circulating anti-OSE antibody levels. 
XBP1 deficiency in B cells increases apoptotic cell accumulation and necrotic core 
We next analyzed the plaque composition in Ldlr-/-/WT and Ldlr-/-/Xbp1B-cKO mice to 
investigate mechanisms involved in enhanced atherosclerosis. Although serum antibody 
levels were significantly reduced in experimental groups (figure 1), residual IgM and IgG may 
still infiltrate atherosclerotic plaques. However, plaque IgM staining was virtually absent in 
Ldlr-/-/Xbp1B-cKO mice (figure 5A). In anti-CD4 depleted mice, IgM was also significantly 
reduced (figure 5A), consistent with results from serum ELISAs (figure 1). IgG1 staining 
(previously shown to be a predominant IgG isotype in plaques43) was also significantly 
reduced in Ldlr-/-/Xbp1B-cKO mice and both anti-CD4 treated groups compared to Ldlr-/-/WT 
(figure 5B). Plaque sections were also analyzed by immunostaining for foam 
cells/macrophages (MOMA2+), smooth muscle cells (α-smooth muscle actin+) and T cells 
(CD3+). There were no differences in the relative proportions of MOMA-2 or α-SMA stained 
areas between any groups (supplemental figure 5A-C). Plaques from Ldlr-/-/Xbp1B-cKO mice 
tended to have increased T cell infiltration (supplemental figure 5D; p=0.053). Most plaque 
infiltrating T cells are CD4+ and consistent with this, the number of plaque CD3+ cells in anti-
CD4 treated mice was very low (data not shown). Despite increased atherosclerotic plaque 
size (suggesting enhanced disease progression towards more complex plaques), Ldlr-/-
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/Xbp1B-cKO and both anti-CD4 treated groups had significantly reduced collagen deposition 
(figure 5C). A potential protective function for antibodies suggested to regulate 
atherosclerosis is the binding and removal of apoptotic or (secondary) necrotic cells2. In 
support of this, the necrotic core area was significantly increased in Ldlr-/-/Xbp1B-cKO, as was 
the level of TUNEL staining within plaques (figure 5D+E). Plaque necrotic core and TUNEL 
staining were also increased in anti-CD4 depleted Ldlr-/-/WT mice (figure 5D+E).  
Since normal plaque progression can heavily influence plaque composition, we determined 
to what extent overall plaque size in each mouse contributed to the difference in plaque 
composition we observed. Thus, we normalized plaque area data of each mouse (data in 
figure 3A) by dividing by the average plaque size for that mouse. Plaque size appeared to 
account for the majority of differences in CD3+ T cell content between Ldlr-/-/WT and Ldlr-/-
/Xbp1B-cKO mice (supplemental figure 5E). However, the levels of necrotic core and TUNEL+ 
staining was still significantly increased in both Ldlr-/-/Xbp1B-cKO (Supplemental Figure 5F+G). 
The reduction in plaque collagen was even more apparent after adjustment for plaque size 
(Supplemental Figure 5H). As an alternative analysis, we also plotted mouse plaque size 
against percentage necrotic core and percentage collagen area using only mice with plaques 
of overlapping levels of atherosclerosis (supplemental figure 6). Plaques of Ldlr-/-/Xbp1B-cKO 
mice displayed higher relative necrotic core area and lower collagen levels than Ldlr-/-/WT 
mouse plaques even though levels still varied with plaque size. This supports the hypothesis 
that reduction in systemic antibodies led to reduced antibody binding within atherosclerotic 
plaques, leading to enhanced accumulation of necrotic cells. 
Discussion 
One of the hallmarks of atherosclerosis is the accumulation and failed clearance of oxidized 
LDL and apoptotic cell debris within the atherosclerotic plaque. Oxidized LDL and apoptotic 
debris are recognized by specific antibodies present in both plasma and atherosclerotic 
plaque. Most recently, protective antibody responses have been specifically associated with 
innate (T cell-independent) pathways such as natural IgM13,44. Our study is the first to 
specifically target plasma cell antibody secretion and to determine the effects of antibody 
deficiency in the presence of all B cell subsets and lymphoid organs. Our results suggest 
that protective antibody responses depend on XBP1-driven plasma cell maturation to a 
highly secretory state and also on CD4+ T cells. We propose that a T cell-driven expansion 
of antibody production is a key protective pathway in response to hyperlipidemia. Both 
cognate and non-cognate T-cell help, which has been implicated in natural IgM expansion, 
may contribute to these responses. 
The B cell receptor senses antigen, which in conjunction with secondary signals, induces the 
activation of antigen-specific B cells, leading to proliferation and subsequent differentiation 
into plasma cells. Plasma cells undergo a profound transcriptional reprogramming, develop 
extensive rough endoplasmic reticulum and Golgi systems, and upregulate both protein 
synthesis and folding machinery, allowing huge levels of antibody secretion34. The loss of 
XBP1 prevents the final stages of this differentiation/maturation pathway, leading to plasma 
cells with severely attenuated secretory capacity35,36. We took advantage of this phenotype 
to specifically interrogate the impacts on atherosclerosis, driven by the chronic and myriad 
accumulation of oxidized lipid antigens. It is reasonable to presume that the antigen burden 
is high in western diet-fed Ldlr-/- mice, and thus antibody consumption would be 
correspondingly rapid. Although low levels of antibodies are produced in Ldlr-/-/Xbp1B-cKO 
mice (figure 1+4 and supplemental figure 1), our results demonstrate this severe reduction in 
production is sufficient to significantly accelerate plaque growth (figure 3) and promote a 
more unstable plaque status (figure 5). Although we cannot completely exclude an 
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alternative impact of XBP1 deficiency on B cell functions independent of plasma cell 
antibody secretion, we believe that together with previous papers, our data strongly indicate 
that other direct effects on B cell functions are minor. A previous report using transgenic 
MD4 hen egg lysozyme-specific B cells suggested a defect in plasma cell homing driven by 
CXCR436, however this was not reproduced in mice with normal B cell repertoires37. 
Although no other studies have previously addressed the effects of a specific defect in 
plasma cells, two previous papers reported enhanced atherosclerosis in mice lacking the 
secreted form of IgM16,17. Indirect but compelling evidence for the importance of IgM is also 
provided by studies showing enhanced atherosclerosis in IL5-deficient mice that have 
reduced IgM11, and reduced atherosclerosis in SiglecG-deficient mice that have increased 
IgM44. In addition, passive transfer of polyclonal IgM reduces atherosclerosis in ApoE-/- 
mice12. However, in sIgM-/- Ldlr-/- mice, impaired clearance of IgE promotes atherosclerosis, 
rather than direct local effects of IgM deficiency17. Compared to sIgM-/- mice, Ldlr-/-/Xbp1B-cKO 
mice have a further deficiency, both in IgE and in all other isotypes of antibodies (figure 1A-
E). This suggests the possibility that IgG antibodies of the same specificity, presumably for 
oxidized epitopes such as MDA or PC, may also make a significant anti-atherosclerotic 
contribution. Studies showing that pneumoccocal immunization of Ldlr-/- mice lead to a 
selective expansion of PC-specific IgM antibodies and reduced atherosclerosis initially 
suggested an important role for IgM antibodies15. However, PC-based and MDA-based 
vaccination strategies that demonstrated an induction of both specific IgM and IgG 
antibodies also resulted in robust lesion reduction43,45. A previous study demonstrated that 
IgG anti-PC binds distinct oxidized epitope containing-determinants on apoptotic cells15. 
Therefore, one explanation could be that the combination of IgM and IgG is most protective.  
The complete lack of all B cell subsets (and therefore antibodies) was reported to increase 
atherosclerosis, both in µMT/Apoe-/- mice46 and after bone marrow transfer of µMT bone 
marrow into Ldlr-/- recipients47. In contrast, a recent study showed reduced atherosclerosis in 
µMT/Apoe-/- mice48. An alternative strategy resulting in attenuated B cell responses is 
splenectomy. Splenectomy enhanced atherosclerosis13,46 and the plaque phenotype was 
similar to Ldlr-/-/Xbp1B-cKO mice (figure 5). The effect of splenectomy can be reversed by 
transfer of splenic B cells from Apoe-/- mice46 or by peritoneal B1a cell transplant13. Given 
these discrepancies, and the influence on non-antibody functions of B cells (µMT mice, 
splenectomy) and remaining adaptive immune responses (sIgM-/- mice) in those studies, our 
model adds important new insight into the influence of endogenous antibody responses. 
Novel advantages of the model used here include the lack of impact on B cell development 
and B cell activation (figure 1 and supplemental figure 3) or on cellular T cell responses 
(figure 2 and supplemental figure 4), which are greatly altered or removed entirely in 
previous models. 
The influence of CD4+ T cells on atherosclerosis is well known to depend on the opposing 
influences of different subsets of effector T cells. Th1-polarized CD4+ T cells producing 
cytokines such as IFN-γ, IL-12 and IL-18 promote atherosclerosis, whereas regulatory T 
cells producing TGF-β and IL-10 dampen plaque growth49,50. Here, we also suggest that 
CD4+ T cells influence atherosclerosis through regulation of antibody responses. Anti-CD4 
depletion reduced IgM, IgG1 and IgG2c antibody levels but neither total IgG nor IgG3 (figure 
1). Anti-CD4 depletion enhanced atherosclerosis, but the combination of anti-CD4 depletion 
and antibody deficiency had no additive effect on atherosclerosis development (figure 3). 
Anti-OSE antibodies in WT mice are primarily produced by B1 cells but adaptive B2 cell 
clones with similar specificity are induced by immunization51, and based on the presence of 
class-switched IgG antibodies, also expand and become plasma cells in atherosclerotic 
mice52. In our study, antibodies against OSE were significantly reduced in a similar way to 
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total antibody levels by both XBP1 deficiency and anti-CD4 depletion.  Previously, MDA-LDL 
immunization induced a prominent Th2-type CD4+ T cell response and an IL-5 dependent 
increase in anti-oxLDL IgM production11, which in vitro was solely produced in response to 
IL-5 by B1a cells. Our study suggests that endogenous protective responses to oxidized LDL 
epitopes may also be enhanced (in a non-cognate manner) by CD4+ T cells. In a similar way 
to immunization, western diet feeding (as used in this study) can switch the T cell response 
in atherosclerotic mice from Th1 to Th253, and a recent study with human B cells showed 
that CD4+ T cells greatly enhance anti-MDA and anti-PC antibody production in vitro54. We 
therefore conclude that CD4+ T cells may play an important and significant role in anti-
atherogenic antibody production. Given the previously demonstrated importance of 
regulatory T cells55, it is possible that part of the pro-atherogenic effect of anti-CD4 depletion 
may be due to the loss of this protective influence, known to be more prominent during the 
time course of this experiment56. Indeed, in the aortic arch, but not the aortic root, there was 
still a (less prominent) increase in atherosclerosis after in CD4 depletion in Ldlr-/-/Xbp1cKO 
mice (figure 4C). However, antibody deficiency did not appear to influence the regulatory T 
cell system (figure 3F), and anti-CD4 depletion did not further increase lesion size or lesion 
composition in the aortic root of Ldlr-/-/Xbp1cKO mice (figure 5 and supplemental figure 5), 
suggesting a prominent role for T cell-dependent antibody responses in regulating 
atherosclerotic development.  
A major protective influence of antibodies on atherosclerosis may derive from the clearance 
of oxLDL and/or secondary necrotic cellular debris. Consistent with this, the major observed 
difference in plaque composition in Ldlr-/-/Xbp1cKO mice was a significant increase in TUNEL 
staining and necrotic core area (figure 5). As plaques progress, smooth muscle cells become 
increasingly synthetic and produce a fibrous cap of collagen important for plaque stability57. 
Here, the increased lesion size in the absence of antibodies was associated with decreased 
proportions of collagen. This further supports the hypothesis that a greater rate of lipid/dead 
cell accumulation led to enhanced atherosclerosis. IgM antibodies may only be important for 
efferocytosis in certain contexts58, for example in atherosclerosis where pathways mediating 
rapid and early apoptotic cell uptake may be defective. Importantly, OSE-specific IgM have 
been shown to enhance the clearance of apoptotic cells by macrophages in vivo59,60. 
Recently, increased anti-phagocytic CD47 on the surface of plaque cells and loss of surface 
Mer tyrosine kinase on plaque phagocytes have been shown to play important roles in 
mouse and human atherosclerosis61,62. These defects lead to secondary necrosis, making 
cells and oxLDL debris recognizable to anti-MDA and anti-PC antibodies. These antibodies 
provide an alternate protective layer that is nevertheless insufficient to prevent 
atherosclerosis progression, however the lack of such antibodies greatly accelerates plaque 
growth.  
The use of the bone marrow transfer model has both advantages and disadvantages, and 
was reported to significantly modulate plaque development63. A developmental lack of 
antibodies and or B cells could have significant influence in lymphoid system development 
and, for example, alternative pathways that regulate apoptotic cell clearance may be 
upregulated. Such changes would be avoided using bone marrow transfer. However, bone 
marrow transfer also induces some changes in the B cell compartment, for example in the 
balance between B1a and B1b cells in the periphery. Nevertheless, similar and corroborating 
findings from BMT and non-BMT studies involving B cells29,30 suggest this model continues 
to provide valuable information. Future studies are required to understand the specific 
contribution of CD4+ T cells and the relative atheroprotective contributions of antibody 
binding to oxLDL versus secondary necrotic cells. 
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In summary, the T cell-dependent humoral response can be protective. Our knowledge of 
the close reciprocal relationship between adaptive B and T cells, and links with innate 
responses, is rapidly evolving. This will enable not only novel and more advanced vaccine 
strategies for atherosclerosis, but also help us to understand the impacts of the growing 
number of immunotherapies used in patients at high risk for cardiovascular disease.  
Acknowledgments 
All flow cytometry was conducted with the assistance of the University of Cambridge Cell 
Phenotyping hub. We are grateful to Maria Osvar-Kozma for assistance with measurements 
of anti-OSE antibodies. 
Sources of Funding 
This study was funded by grants from the British Heart Foundation to APS and ZM. 
Disclosures 
None 
References 
1.  Clarke M, Talib S, Figg N, Bennett M. Vascular Smooth Muscle Cell Apoptosis 
Induces Interleukin-1–Directed Inflammation Effects of Hyperlipidemia-Mediated 
Inhibition of Phagocytosis. Circ Res. 2010; 106:363–372.  
2.  Binder CJ, Papac-Milicevic N, Witztum JL. Innate sensing of oxidation-specific 
epitopes in health and disease. Nat. Rev. Immunol. 2016; 16:485–97.  
3.  Hooijkaas, Benner, Pleasants, Wostmann. Isotypes and specificities of 
immunoglobulins produced by germ-free mice fed chemically defined ultrafiltered 
“antigen-free” diet. Eur J Immunol. 1984; 14:1127–30.  
4.  Vinuesa CG, Linterman MA, Yu D, MacLennan IC. Follicular Helper T Cells. 
Annu. Rev. Immunol. 2016; 
5.  Karvonen J, Päivänsalo M, Kesäniemi A, Hörkkö S. Immunoglobulin M type of 
autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid 
artery atherosclerosis. Circulation. 2003; 108:2107–12.  
6.  Su J, Georgiades A, Wu R, Thulin T, de Faire U, Frostegård J. Antibodies of 
IgM subclass to phosphorylcholine and oxidized LDL are protective factors for 
atherosclerosis in patients with hypertension. Atherosclerosis. 2005; 188:160–6.  
7.  Rahman M, Sing S, Golabkesh Z, Fiskesund R, Gustafsson T, Jogestrand T, 
Frostegård AG, Hafström I, Liu A, Frostegård J. IgM antibodies against 
malondialdehyde and phosphorylcholine are together strong protection markers for 
atherosclerosis in systemic lupus erythematosus: Regulation and underlying 
mechanisms. Clin. Immunol. 2016; 
8.  Ravandi A, Boekholdt M, Mallat Z, Talmud P, Kastelein J, Wareham N, Miller 
E, Benessiano J, Tedgui A, Witztum J, Khaw K-T, Tsimikas S. Relationship of IgG 
and IgM autoantibodies and immune complexes to oxidized LDL with markers of 
oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk 
Study. J Lipid Res. 2011; 52:1829–1836.  
9.  Khamis R, Hughes A, Caga-Anan M, Chang C, Boyle J, Kojima C, Welsh P, 
Sattar N, Johns M, Sever P, Mayet J, Haskard D. High Serum Immunoglobulin G 
and M Levels Predict Freedom From Adverse Cardiovascular Events in 
Hypertension: A Nested Case-Control Substudy of the Anglo-Scandinavian Cardiac 
Outcomes Trial. Ebiomedicine. 2016; 9:372–380.  
 Sage et al_310884/R1       13 
 
13 
 
10.  Lehtimäki, Lehtinen, Solakivi, Nikkilä, Jaakkola, Jokela, Ylä-Herttuala, Luoma, 
Koivula, Nikkari. Autoantibodies against oxidized low density lipoprotein in patients 
with angiographically verified coronary artery disease. Arteriosclerosis Thrombosis 
Vasc Biology. 1999; 19:23–7.  
11.  Binder CJ, Hartvigsen K, Chang M-KK, Miller M, Broide D, Palinski W, Curtiss 
LK, Corr M, Witztum JL. IL-5 links adaptive and natural immunity specific for 
epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 2004; 
114:427–37.  
12.  Cesena F, Dimayuga P, Yano J, Zhao X, Kirzner J, Zhou J, Chan L, Lio W, 
Cercek B, Shah P, Chyu K-Y. Immune-modulation by polyclonal IgM treatment 
reduces atherosclerosis in hypercholesterolemic apoE-/- mice. Atherosclerosis. 
2012; 220:59–65.  
13.  Kyaw T, Tay C, Krishnamurthi S, Kanellakis P, Agrotis A, Tipping P, Bobik A, 
Toh B-H. B1a B lymphocytes are atheroprotective by secreting natural IgM that 
increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. 
Circulation research. 2011; 109:830–40.  
14.  Rosenfeld SM, Perry HM, Gonen A, Prohaska TA, Srikakulapu P, Grewal S, 
Das D, McSkimming C, Taylor AM, Tsimikas S, Bender TP, Witztum JL, McNamara 
CA. B-1b Cells Secrete Atheroprotective IgM and Attenuate Atherosclerosis. Circ. 
Res. 2015; 117:e28–39.  
15.  Binder C, Hörkkö S, Dewan A, Chang M-K, Kieu E, Goodyear C, Shaw P, 
Palinski W, Witztum J, Silverman G. Pneumococcal vaccination decreases 
atherosclerotic lesion formation: molecular mimicry between Streptococcus 
pneumoniae and oxidized LDL. Nat Med. 2003; 9:736–743.  
16.  Lewis M, Malik T, Ehrenstein M, Boyle J, Botto M, Haskard D. 
Immunoglobulin M is required for protection against atherosclerosis in low-density 
lipoprotein receptor-deficient mice. Circulation. 2009; 120:417–26.  
17.  Tsiantoulas D, Bot I, Ozsvar Kozma M, Goederle L, Perkmann T, Hartvigsen 
K, Conrad DH, Kuiper J, Mallat Z, Binder CJ. Increased Plasma IgE Accelerate 
Atherosclerosis in Secreted IgM Deficiency. Circ. Res. 2016; 
18.  Schiopu A, Bengtsson J, Söderberg I, Janciauskiene S, Lindgren S, Ares M, 
Shah P, Carlsson R, Nilsson J, Fredrikson G. Recombinant human antibodies 
against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit 
atherosclerosis. Circulation. 2004; 110:2047–52.  
19.  Tsimikas S, Miyanohara A, Hartvigsen K, Merki E, Shaw P, Chou M-Y, 
Pattison J, Torzewski M, Sollors J, Friedmann T, Lai C, Hammond K, Getz G, 
Reardon C, Li A, Banka C, Witztum J. Human Oxidation-Specific Antibodies Reduce 
Foam Cell Formation and Atherosclerosis Progression. Journal of the American 
College of Cardiology. 2011; 58:1715–1727.  
20.  Kelly J, Griffin M, Fava R, Wood S, Bessette K, Miller E, Huber S, Binder C, 
Witztum J, Morganelli P. Inhibition of arterial lesion progression in CD16-deficient 
mice: evidence for altered immunity and the role of IL-10. Cardiovascular research. 
2010; 85:224–31.  
21.  Mendez-Fernandez Y, Stevenson B, Diehl C, Braun N, Wade N, Covarrubias 
R, van Leuven S, Witztum J, Major A. The inhibitory FcγRIIb modulates the 
inflammatory response and influences atherosclerosis in male apoE(-/-) mice. 
Atherosclerosis. 2011; 214:73–80.  
22.  Merched A, Daret D, Li L, Franzl N, Sauvage-Merched M. Specific 
autoantigens in experimental autoimmunity-associated atherosclerosis. Faseb J. 
2016; 30:2123–2134.  
 Sage et al_310884/R1       14 
 
14 
 
23.  Callaghan C, Win T, Motallebzadeh R, Conlon T, Chhabra M, Harper I, 
Sivaganesh S, Bolton E, Bradley A, Brownlie R, Smith K, Pettigrew G. Regulation of 
Allograft Survival by Inhibitory FcγRIIb Signaling. J Immunol. 2012; 189:5694–5702.  
24.  Gulati A, Bagga A. Large vessel vasculitis. Pediatric Nephrol Berlin Ger. 2009; 
25:1037–48.  
25.  Tsiantoulas D, Sage AP, Mallat Z, Binder CJ. Targeting B cells in 
atherosclerosis: closing the gap from bench to bedside. Arterioscler. Thromb. Vasc. 
Biol. 2015; 35:296–302.  
26.  Lykken J, DiLillo D, Weimer E, Roser-Page S, Heise M, Grayson J, 
Weitzmann, Tedder T. Acute and chronic B cell depletion disrupts CD4+ and CD8+ T 
cell homeostasis and expansion during acute viral infection in mice. Journal of 
immunology (Baltimore, Md. : 1950). 2014; 193:746–56.  
27.  Lund F, Randall T. Effector and regulatory B cells: modulators of CD4+ T cell 
immunity. Nature reviews. Immunology. 2010; 10:236–47.  
28.  Ait-Oufella H, Herbin O, Bouaziz J-D, Binder C, Uyttenhove C, Laurans L, 
Taleb S, Vré E, Esposito B, Vilar J, Sirvent J, Snick J, Tedgui A, Tedder T, Mallat Z. 
B cell depletion reduces the development of atherosclerosis in mice. The Journal of 
Experimental Medicine. 2010; 207:1579–1587.  
29.  Sage AP, Tsiantoulas D, Baker L, Harrison J, Masters L, Murphy D, Loinard 
C, Binder CJ, Mallat Z. BAFF receptor deficiency reduces the development of 
atherosclerosis in mice--brief report. Arterioscler. Thromb. Vasc. Biol. 2012; 
32:1573–6.  
30.  Kyaw T, Tay C, Hosseini H, Kanellakis P, Gadowski T, MacKay F, Tipping P, 
Bobik A, Toh B-H. Depletion of B2 but not B1a B cells in BAFF receptor-deficient 
ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation. 
PloS one. 2012; 7:e29371.  
31.  Clement M, Guedj K, Andreata F, Morvan M, Bey L, Khallou-Laschet J, 
Gaston A-TT, Delbosc S, Alsac J-MM, Bruneval P, Deschildre C, Le Borgne M, 
Castier Y, Kim H-JJ, Cantor H, Michel J-BB, Caligiuri G, Nicoletti A. Control of the 
Tfh-GC B Cell Axis by CD8+ Tregs Limits Atherosclerosis and Tertiary Lymphoid 
Organ Development. Circulation. 2014; 
32.  Hilgendorf I, Theurl I, Gerhardt L, Robbins C, Weber G, Gonen A, Iwamoto Y, 
Degousee N, Holderried T, Winter C, Zirlik A, Lin H, Sukhova G, Butany J, Rubin B, 
Witztum J, Libby P, Nahrendorf M, Weissleder R, Swirski F. Innate Response 
Activator B Cells Aggravate Atherosclerosis by Stimulating T Helper-1 Adaptive 
Immunity. Circulation. 2014; 129:1677–1687.  
33.  Nus M, Sage A, Lu Y, Masters L, Lam B, Newland S, Weller S, Tsiantoulas D, 
Raffort J, Marcus D, Finigan A, Kitt L, Figg N, Schirmbeck R, Kneilling M, Yeo G, 
Binder C, de la Pompa J, Mallat Z. Marginal zone B cells control the response of 
follicular helper T cells to a high-cholesterol diet. Nat Med. 2017; 
34.  Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of 
antibody-secreting plasma cells. Nat. Rev. Immunol. 2015; 15:160–71.  
35.  Todd D, McHeyzer-Williams L, Kowal C, Lee A-H, Volpe B, Diamond B, 
McHeyzer-Williams M, Glimcher L. XBP1 governs late events in plasma cell 
differentiation and is not required for antigen-specific memory B cell development. J 
Exp Medicine. 2009; 206:2151–2159.  
36.  Hu C, Dougan S, McGehee A, Love C, Ploegh H. XBP‐1 regulates signal 
transduction, transcription factors and bone marrow colonization in B cells. The 
EMBO Journal. 2009; 28:1624–1636.  
 Sage et al_310884/R1       15 
 
15 
 
37.  Taubenheim N, Tarlinton D, Crawford S, Corcoran L, Hodgkin P, Nutt S. High 
Rate of Antibody Secretion Is not Integral to Plasma Cell Differentiation as Revealed 
by XBP-1 Deficiency. J Immunol. 2012; 189:3328–3338.  
38.  Hobeika, Thiemann, Storch, Jumaa, Nielsen, Pelanda, Reth. Testing gene 
function early in the B cell lineage in mb1-cre mice. Proceedings of the National 
Academy of Sciences of the United States of America. 2006; 103:13789–94.  
39.  Hetz C, Lee A-H, Gonzalez-Romero D, Thielen P, Castilla J, Soto C, Glimcher 
L. Unfolded protein response transcription factor XBP-1 does not influence prion 
replication or pathogenesis. Proc National Acad Sci. 2008; 105:757–762.  
40.  Sage AP, Murphy D, Maffia P, Masters LM, Sabir SR, Baker LL, Cambrook H, 
Finigan AJ, Ait-Oufella H, Grassia G, Harrison JE, Ludewig B, Reith W, Hansson 
GK, Reizis B, Hugues S, Mallat Z. MHC Class II-restricted antigen presentation by 
plasmacytoid dendritic cells drives proatherogenic T cell immunity. Circulation. 2014; 
130:1363–73.  
41.  Grasset EK, Duhlin A, Agardh HE, Ovchinnikova O, Hägglöf T, Forsell MN, 
Paulsson-Berne G, Hansson GK, Ketelhuth DF, Karlsson MC. Sterile inflammation in 
the spleen during atherosclerosis provides oxidation-specific epitopes that induce a 
protective B-cell response. Proc. Natl. Acad. Sci. U.S.A. 2015; 112:E2030–8.  
42.  Darrasse-Jèze G, Deroubaix S, Mouquet H, Victora G, Eisenreich T, Yao K, 
Masilamani R, Dustin M, Rudensky A, Liu K, Nussenzweig M. Feedback control of 
regulatory T cell homeostasis by dendritic cells in vivo. The Journal of Experimental 
Medicine. 2009; 206:1853–1862.  
43.  Gonen A, Hansen L, Turner W, Montano E, Que X, Rafia A, Chou M-Y, 
Wiesner P, Tsiantoulas D, Corr M, VanNieuwenhze M, Tsimikas S, Binder C, 
Witztum J, Hartvigsen K. Atheroprotective immunization with malondialdehyde-
modified LDL is hapten specific and dependent on advanced MDA adducts: 
implications for development of an atheroprotective vaccine. J Lipid Res. 2014; 
55:2137–2155.  
44.  Gruber S, Hendrikx T, Tsiantoulas D, Ozsvar-Kozma M, Göderle L, Mallat Z, 
Witztum J, Shiri-Sverdlov R, Nitschke L, Binder C. Sialic Acid-Binding 
Immunoglobulin-like Lectin G Promotes Atherosclerosis and Liver Inflammation by 
Suppressing the Protective Functions of B-1 Cells. Cell Reports. 2016; 14:2348–
2361.  
45.  Caligiuri G, Khallou-Laschet J, Vandaele M, Gaston A-T, Delignat S, Mandet 
C, Kohler H, Kaveri S, Nicoletti A. Phosphorylcholine-Targeting Immunization 
Reduces Atherosclerosis. J Am Coll Cardiol. 2007; 50:540–546.  
46.  Caligiuri. Protective immunity against atherosclerosis carried by B cells of 
hypercholesterolemic mice. Journal of Clinical Investigation. 2002; 109.  
47.  Major A, Fazio S, Linton M. B-Lymphocyte Deficiency Increases 
Atherosclerosis in LDL Receptor–Null Mice. Arteriosclerosis Thrombosis Vasc 
Biology. 2002; 22:1892–1898.  
48.  Tay C, Liu Y-H, Hosseini H, Kanellakis P, Cao A, Peter K, Tipping P, Bobik A, 
Toh B-H, Kyaw T. B-cell-specific depletion of tumour necrosis factor alpha inhibits 
atherosclerosis development and plaque vulnerability to rupture by reducing cell 
death and inflammation. Cardiovasc Res. 2016; 111:385–97.  
49.  Legein B, Temmerman L, Biessen EA, Lutgens E. Inflammation and immune 
system interactions in atherosclerosis. Cell. Mol. Life Sci. 2013; 70:3847–69.  
50.  Ait-Oufella H, Sage AP, Mallat Z, Tedgui A. Adaptive (T and B cells) immunity 
and control by dendritic cells in atherosclerosis. Circ. Res. 2014; 114:1640–60.  
 Sage et al_310884/R1       16 
 
16 
 
51.  Zhou X, Caligiuri G, Hamsten A, Lefvert A, Hansson G. LDL Immunization 
Induces T-Cell–Dependent Antibody Formation and Protection Against 
Atherosclerosis. Arteriosclerosis Thrombosis Vasc Biology. 2001; 21:108–114.  
52.  Lewis MJ, Malik TH, Fossati-Jimack L, Carassiti D, Cook HT, Haskard DO, 
Botto M. Distinct roles for complement in glomerulonephritis and atherosclerosis 
revealed in mice with a combination of lupus and hyperlipidemia. Arthritis Rheum. 
2012; 64:2707–18.  
53.  Zhou, Paulsson, Stemme, Hansson. Hypercholesterolemia is associated with 
a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-
knockout mice. Journal of Clinical Investigation. 1998; 101:1717–25.  
54.  Fiskesund, Steen, Amara, Murray, Szwajda. Naturally occurring human 
phosphorylcholine antibodies are predominantly products of affinity-matured B cells 
in the adult. J Immunol. 2014; 
55.  Ait-Oufella H, Salomon BL, Potteaux S, Robertson A-KLK, Gourdy P, Zoll J, 
Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, 
Tedgui A, Mallat Z. Natural regulatory T cells control the development of 
atherosclerosis in mice. Nat. Med. 2006; 12:178–80.  
56.  Maganto-García E, Tarrio M, Grabie N, Bu D, Lichtman A. Dynamic changes 
in regulatory T cells are linked to levels of diet-induced hypercholesterolemia. 
Circulation. 2011; 124:185–95.  
57.  Adiguzel E, Ahmad P, Franco C, Bendeck M. Collagens in the progression 
and complications of atherosclerosis. Vasc Med. 2009; 14:73–89.  
58.  Hesketh E, Dransfield I, Kluth D, Hughes J. Circulating IgM Requires Plasma 
Membrane Disruption to Bind Apoptotic and Non-Apoptotic Nucleated Cells and 
Erythrocytes. Plos One. 2015; 10:e0131849.  
59.  Ogden C, Kowalewski R, Peng Y, Montenegro V, Elkon K. IGM is required for 
efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity. 
2005; 38:259–64.  
60.  Chou M-Y, Fogelstrand L, Hartvigsen K, Hansen L, Woelkers D, Shaw P, 
Choi J, Perkmann T, Bäckhed F, Miller Y, Hörkkö S, Corr M, Witztum J, Binder C. 
Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice 
and humans. J Clin Invest. 2009; 119:1335–1349.  
61.  Kojima Y, Volkmer J-P, McKenna K, Civelek M, Lusis A, Miller C, Direnzo D, 
Nanda V, Ye J, Connolly A, Schadt E, Quertermous T, Betancur P, Maegdefessel L, 
Matic L, Hedin U, Weissman I, Leeper N. CD47-blocking antibodies restore 
phagocytosis and prevent atherosclerosis. Nature. 2016; 536:86–90.  
62.  Cai B, Thorp E, Doran A, Sansbury B, Daemen M, Dorweiler B, Spite M, 
Fredman G, Tabas I. MerTK receptor cleavage promotes plaque necrosis and 
defective resolution in atherosclerosis. Journal of Clinical Investigation. 2017; 
63.  Schiller, Kubo, Boisvert, Curtiss. Effect of gamma-irradiation and bone 
marrow transplantation on atherosclerosis in LDL receptor-deficient mice. 
Arteriosclerosis, thrombosis, and vascular biology. 2001; 21:1674–80.  
 
 
  
 Sage et al_310884/R1       17 
 
17 
 
 
 Sage et al_310884/R1       18 
 
18 
 
  
 Sage et al_310884/R1       19 
 
19 
 
  
 Sage et al_310884/R1       20 
 
20 
 
  
 Sage et al_310884/R1       21 
 
21 
 
 
